Category Archives: DPP-IVi

Merck’s Januvia Receives CRL from FDA for TECOS

Merck has announced it received a complete response letter (CRL) regarding its submission of data from the TECOS cardiovascular outcomes trial for Januvia (sitagliptin). The company has not disclosed the reason for the CRL, but said it is working with FDA to discuss next steps.

This content is for Read Less members only.
Register
Already a member? Log in here

Merck Q4 ’16 Earnings Update

Merck hosted their Q4 and full-year 2016 earnings update today. Overall, there was minimal diabetes-related discussion as the primary focus was on Keytruda.

This content is for Read Less members only.
Register
Already a member? Log in here